Coherus BioSciences Inc. (NASDAQ:CHRS) and Mustang Bio Inc. (NASDAQ:MBIO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

The Current Ratio and Quick Ratio of Coherus BioSciences Inc. are 5.3 and 5.3 respectively. Its competitor Mustang Bio Inc.?s Current Ratio is 10.3 and its Quick Ratio is 10.3. Mustang Bio Inc. can pay off short and long-term obligations better than Coherus BioSciences Inc.

Analyst Ratings

The Ratings and Recommendations for Coherus BioSciences Inc. and Mustang Bio Inc. are featured in the next table.

Roughly 98.8% of Coherus BioSciences Inc. shares are held by institutional investors while 9.6% of Mustang Bio Inc. are owned by institutional investors. 0.4% are Coherus BioSciences Inc.’s share held by insiders. Comparatively, 1.1% are Mustang Bio Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W)

Performance (M)

Performance (Q)

Performance (HY)

Performance (Y)

Performance (YTD)

Coherus BioSciences Inc.

1.49%

11.66%

36.64%

-25.41%

53.37%

66.08%

Mustang Bio Inc.

-13.73%

1.34%

-2.08%

-45.36%

-64.63%

28.23%

For the past year Coherus BioSciences Inc. was more bullish than Mustang Bio Inc.

Summary

On 6 of the 8 factors Mustang Bio Inc. beats Coherus BioSciences Inc.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companys product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohns Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.